Skip to main content

Longitudinal Innate Immunity and Aging Study (LIIA)


This observational study plans to examine the biological bases of cognitive aging. The goals of the study are to better understand how immune system markers, measured in the blood and in cerebrospinal fluid, are related to clinical features of aging over time.

Minimum Age Maximum Age Gender Healthy Volunteers
65 Years 89 Years All Yes
April 30, 2019
May 31, 2024

  • Study partner with contact at least twice per month who can provide information about functional abilities
  • Mini-Mental State Examination score greater than 25
  • Clinical Dementia Rating global score of 0 5
  • No significant cognitive decline in last year
  • No evidence of a neurodegenerative disorder

  • Major psychiatric disorder, such as schizophrenia, bipolar disorder, or untreated major depression in past year
  • Neurological conditions affecting cognition, including Parkinson's disease, epilepsy (onset prior than 2 years ago), head trauma with loss of consciousness longer than 5 minutes, large vessel infarct, mild cognitive impairment, or dementia
  • Central nervous system (CNS) immune conditions and other conditions affecting cognition, such as multiple sclerosis, paraneoplastic encephalitides, Hashimoto's thyroiditis, and systematic lupus erythematosus
  • Systematic illness, such as current cancer, kidney failure, or respiratory failure
  • Substance abuse/dependence
  • Prohibited medications: drugs likely to affect the CNS (e.g., long-acting benzodiazepines, neuroleptics in the phenothiazine and haloperidol families); anticoagulants, antiplatelets, heparin shots, or other blood thinner medications (e.g., warfarin, dabigatran, rivaroxaban, apixaban, clopidogrel)
  • Significant hearing, visual, or motor deficits that would interfere with cognitive testing
  • Factors that preclude magnetic resonance imaging (e.g., pacemaker or metal implants)
  • Factors that preclude lumbar puncture (e.g., infection at puncture site)

Participants will undergo a series of tests and assessments over a 2-year period. Researchers will measure levels of immune markers in blood and cerebrospinal fluid and changes in cognitive function. They will also examine changes in brain structure and levels of proteins associated with Alzheimer's disease. This research may ultimately help scientists better understand what puts individuals at risk for cognitive decline and Alzheimer's disease.

Name City State Zip Status Primary Contact
University of Colorado Anschutz Medical Campus
Aurora Colorado 80045 Recruiting Katrina Bengtson

University of Colorado, Denver

  • National Institute on Aging (NIA)

Name Phone Email
Nicola Haakonsen 303-724-4644
Katrina Bengtson 303-724-2048


Investigating the Contribution of Peripheral Central Nervous System Dysfunction to Cognitive Aging